title: Effects of some antioxidative aporphine derivatives on striatal dopaminergic transmission and on MPTP-induced striatal dopamine depletion in B6CBA mice.
abstract: (S)-(+)-boldine, an aporphine alkaloid displaying antioxidative and dopaminergic properties, and six of its derivatives (glaucine, 3-bromoboldine, 3-iodoboldine, 8-aminoboldine, 8-nitrosoboldine and 2,9-O,O'-dipivaloylboldine) were tested for these properties in comparison with their parent compound. All the tested compounds displayed in vitro antioxidative properties equal to or slightly weaker than those of boldine, and equal to or stronger than (+/-)-6-hydroxy-2,5,7,8,-tetramethylchromane-2-carboxylic acid (Trolox), a water-soluble vitamin E analogue, used as a reference compound. All the aporphine compounds tested displaced [3H]SCH 23390 and [3H]raclopride from their specific binding sites in rat striatum. When tested on dopamine (DA) metabolism in the striatum of B6CBA mice, all the compounds, except 8-aminoboldine, increased striatal levels of DOPAC and HVA, and the HVA/DA ratio, indicating that they cross the blood-brain barrier and that they seem to act as dopamine antagonists in vivo. B6CBA mice were sensitive to the neurotoxic action of MPTP on dopaminergic neurons as indicated by the strongly decreased striatal levels of DA, DOPAC and HVA following administration of MPTP (20 mg/kg, i.p.). Among these aporphine derivatives, only 3-bromoboldine was able to reduce the MPTP-induced decrease of striatal levels of DA and DOPAC, whereas (R)-apomorphine (5 mg/kg, s.c.) and acetylsalicylic acid (100 mg/kg, i.p.), used as reference compounds, were very active. These data suggest that potent in vitro antioxidative properties and the ability to cross the blood-brain barrier are not sufficient criteria to predict the inhibition of neuronal degeneration induced by MPTP.
authors.affiliation: Toxicology Laboratory, Faculty of Pharmacy, University of Medicine and Pharmacy, 3400 Cluj-Napoca, Romania.
authors.forename: Felicia
authors.initials: F
authors.lastname: Loghin
authors.forename: Abdeslam
authors.initials: A
authors.lastname: Chagraoui
authors.forename: Marcelo
authors.initials: M
authors.lastname: Asencio
authors.forename: Etienne
authors.initials: E
authors.lastname: Comoy
authors.forename: Hernan
authors.initials: H
authors.lastname: Speisky
authors.forename: Bruce K
authors.initials: BK
authors.lastname: Cassels
authors.forename: Philippe
authors.initials: P
authors.lastname: Protais
mesh_terms: D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000494:pharmacology*; D000818:Animals; D000975:Antioxidants / Q000737:chemistry / Q000494:pharmacology*; D001060:Aporphines / Q000737:chemistry / Q000494:pharmacology*; D003342:Corpus Striatum / Q000187:drug effects* / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008808:Mice, Inbred CBA; D024301:Plant Bark; D010936:Plant Extracts / Q000494:pharmacology
chemical_list: D000975:Antioxidants; D001060:Aporphines; D010936:Plant Extracts; C081279:aporphine; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D004298:Dopamine